Portofolio **hPD-1** mouse models

genOway | ULTIMATE PREDICTABILITY

Support your PD-1 PROGRAM through its preclinical journey with the right PD-1 model at each scientific step

thanks to genOway's unique portfolio of humanized PD-1 mouse models

Key scientific questions → **Preclinical journey** supported by **genOway's program-based approach** → **Relevant preclinical data**

	POC studies	Advanced studies: Multiple ICPs	Advanced studies: T cell engagers	Advanced studies: Antibody design & optimization
Efficacy **Safety** **PK** **Biodistribution**	The **genO-hPD-1** reference mouse model	Advanced **hPD-1** mouse models with other **humanized immune checkpoints**	Advanced **hPD-1** mouse models with **humanized CD3**	Advanced **hPD-1** mouse models with **humanized Fc receptors**
Compatible humanized tumor cell lines				



Our program-based approach:

- **Free scientific expertise at your disposal:** for selecting the right model, running you through the extensive data package, and securing your experimental design
- Possible **crossbreeding rights with your established models:** request for options
- **New models in development.** Please ask for information if you didn't find what you were looking for

What makes our portfolio of humanized PD-1 mouse models unique

- ☑ **Physiological expression of humanized targets:** More clinically relevant biology
- ☑ **Robust, extensive validation data generated in-house/with biopharma partners:** De-risk your development program
- ☑ **Fully immunocompetent:** preserve authentic tumor-immune interactions

Easy, quick and secure access: models produced by professional breeders **in US and Europe** with certified health status and immediately available for door-to-door delivery to your facility or the CRO of your choice

Evaluated by **10+** **leading biopharma companies** with over **7 YEARS** **of track record**

Scan or click to access the **genO-hPD-1 portfolio**

genOway | ULTIMATE PREDICTABILITY

genO-hPD-1 portfolio (scan or click)

Find the right PD-1 model for your program

genO-hPD-1: the reference humanized PD-1 mouse

ASSESS PD-1-TARGETING THERAPIES IN IMMUNO-ONCOLOGY, IMMUNOLOGY AND INFLAMMATION

Originally developed for **Bristol-Myers Squibb** to **evaluate Opdivo®** (nivolumab), the model became the foundation of the **genO-hPD-1 portfolio**.

It has since been used extensively by leading biopharmaceutical and biotechnology companies, including **two IND filings** by **Anaveon** and **Seismic Therapeutic**, as well as by **CRO companies**.

Bristol Myers Squibb · ANAVEON · SEISMIC THERAPEUTIC · janssen · charles river

Advanced versions of the genO-hPD-1 model for more precise and translatable results

Advanced hPD-1 models with other humanized immune checkpoints

genO-hPD-1/...

hPD-L1 · hCTLA-4 · hLAG-3 · hTIM-3 · hGITR/hGITRL · hVISTA · hICOS

EXPLORE COMBINATION AND MULTI-CHECKPOINT STRATEGIES

Evaluate the efficacy and safety of therapies targeting PD-1 alongside another immune checkpoint, with physiological expression of both humanized targets.

CLIENT REFERENCES

AstraZeneca — genO-hPD-1/hCTLA-4

abbvie — genO-hPD-1 & genO-hPD-1/hGITR/hGITRL

Roche — genO-hPD-1/hLAG-3 & genO-hPD-1/hTIM-3

BONUM — genO-hPD-1/hLAG-3

Advanced hPD-1 models with humanized CD3

genO-panhCD3/...

hPD-1 · hPD-1/hPD-L1

EVALUATE T-CELL-ENGAGING THERAPEUTICS

Combine **humanized PD-1** biology with the **genO-panhCD3** reference model to investigate therapeutics whose activity depends on **engagement of human T cells**, such as bispecific antibodies and T-cell engagers.

Based on the reference **genO-panhCD3 mouse model** which has been **extensively validated.**

CLIENT REFERENCES

AstraZeneca · zymeworks · IMN Istituto di Ricerche Farmacologiche Mario Negri - IRCCS · Seattle Children's Hospital • Research • Foundation

All with genO-panhCD3

Advanced hPD-1 models with humanized Fc receptors

genO-hPD-1/...

hFcγR

ASSESS BOTH TARGET ENGAGEMENT AND Fc EFFECTOR FUNCTION

Combine humanized PD-1 with the **genO-hFcγR mouse model** to evaluate therapies whose efficacy depends on both PD-1 targeting and Fc-mediated activity.

Based on the reference **genO-hFcγR mouse model**, which has been **extensively validated.**

CLIENT REFERENCES

argenx · asylia THERAPEUTICS · VIB · Vir Biotechnology™ · innate pharma

All with genO-hFcγR

Compatible humanized tumor cell lines


genO-MC38/...

hPD-L1-hCD47-LZ · hPD-L1-hHER2-LZ · hPD-L1-hFAP-LZ · hFAP-LZ · hPD-L1 · hPD-L1-LZ

genO-CT26/...

hPD-L1 · Pd-l1KO

Pair your selected model with compatible humanized cell lines for syngeneic efficacy studies and build a more integrated, translational preclinical strategy.



WWW.GENOWAY.COM For more information, visit genOway website or contact us